Study Design
This trial was designed as a single-center, open-label, nonrandomized, parallel-group study. Ten healthy subjects with normal renal function, defined by estimated glomerular filtration rate (eGFR) ≥ 90 mL/min/, and 10 subjects with severe renal impairment or end-stage renal disease (eGFR ≤ 30 mL/min/) received a single oral dose of 0.5 g nemonoxacin capsule. eGFR was calculated by the Chronic Kidney Disease Epidemiology Collaboration equation.